secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2021-10-25T23:59:59+00:00
Accession:  0000950170-21-002256
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Clearside's XIPERE for macular edema associated with uveitis; first suprachoroidal therapy
--------------------------------------------------------------------------------

- XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.
- Phase 3 PEACHTREE trial: 47% of XIPERE patients achieved ≥15-letter BCVA improvement vs 16% sham (p<0.01) at Week 24.
- Bausch + Lomb markets XIPERE; expected availability Q1 2022 under Clearside's SCS Microinjector delivery system.
- This is Clearside's first commercial product and the first approved treatment specifically for macular edema associated with uveitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/0000950170-21-002256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/clsd-20211025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-002256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer